Mesothelioma Symptoms - Revision history

MesotheliomaSupport: Internal linking: added 4 wiki links

2026-02-20T20:56:33Z

Internal linking: added 4 wiki links

← Older revision		Revision as of 20:56, 20 February 2026
Line 42:		Line 42:
	== Executive Summary ==		== Executive Summary ==

	[[Mesothelioma]] symptoms are notoriously nonspecific and frequently misdiagnosed, contributing to a diagnostic delay averaging 9 months from initial symptom onset.<ref name="ncimeso">[https://www.cancer.gov/types/mesothelioma Malignant Mesothelioma Treatment (PDQ) – Health Professional Version, National Cancer Institute]</ref> Pleural mesothelioma accounts for approximately 81% of cases and typically presents with progressive dyspnea (59%), chest pain (53%), and pleural effusion (86%).<ref name="dandellsymptoms">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-symptoms-guide/ Mesothelioma Symptoms Guide \| Danziger & De Llano]</ref><ref name="pmcsymptoms">[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090860/ Garcia-Prieto CA, et al. Clinical characteristics and outcomes in malignant pleural mesothelioma: a single-center experience. ''Cancers.'' 2024;16(9):1712.]</ref> Peritoneal mesothelioma affects 15-20% of patients with abdominal pain (69%) and ascites (77%) as predominant features, while pericardial and testicular variants represent fewer than 2% of cases each and are frequently diagnosed posthumously.<ref name="mesonetperitoneal">[https://mesothelioma.net/peritoneal-mesothelioma/ Peritoneal Mesothelioma \| Mesothelioma.net]</ref> Approximately 25% of mesothelioma patients receive an initial misdiagnosis, often as pneumonia, COPD, or lung cancer, delaying definitive treatment and reducing survival options.<ref name="dandelldiagnosis">[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Information \| Danziger & De Llano]</ref><ref name="ncimeso" /> Histological cell type—epithelioid (70-80%), sarcomatoid (10-15%), or biphasic (10-15%)—substantially affects prognosis and symptom severity, with sarcomatoid variants presenting earlier with more aggressive pain and constitutional symptoms.<ref name="mlcdiseases">[https://www.mesotheliomalawyercenter.org/asbestos/diseases/ Asbestos-Related Diseases \| Mesothelioma Lawyer Center]</ref><ref name="ncimeso" /> Emerging biomarker advances in 2024-2026, including circulating microRNA panels, volatile organic compound breath analysis, and chromosomal rearrangement liquid biopsy, may enable earlier detection in high-risk asbestos-exposed populations.<ref name="mesoattsymptoms">[https://mesotheliomaattorney.com/mesothelioma/symptoms/ Mesothelioma Symptoms \| Mesothelioma Attorney]</ref><ref name="pmcbiomarkers">[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504120/ Chen Z, Gaudino G, Pass HI, et al. Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. ''Transl Lung Cancer Res.'' 2017;6(3):259-269.]</ref> Early recognition of symptoms and immediate medical consultation are critical for treatment eligibility and preserving legal claims.		[[Mesothelioma]] symptoms are notoriously nonspecific and frequently misdiagnosed, contributing to a diagnostic delay averaging 9 months from initial symptom onset.<ref name="ncimeso">[https://www.cancer.gov/types/mesothelioma Malignant Mesothelioma Treatment (PDQ) – Health Professional Version, National Cancer Institute]</ref> Pleural [[Mesothelioma\|mesothelioma]] accounts for approximately 81% of cases and typically presents with progressive dyspnea (59%), chest pain (53%), and pleural effusion (86%).<ref name="dandellsymptoms">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-symptoms-guide/ Mesothelioma Symptoms Guide \| Danziger & De Llano]</ref><ref name="pmcsymptoms">[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090860/ Garcia-Prieto CA, et al. Clinical characteristics and outcomes in malignant pleural mesothelioma: a single-center experience. ''Cancers.'' 2024;16(9):1712.]</ref> Peritoneal mesothelioma affects 15-20% of patients with abdominal pain (69%) and ascites (77%) as predominant features, while pericardial and testicular variants represent fewer than 2% of cases each and are frequently diagnosed posthumously.<ref name="mesonetperitoneal">[https://mesothelioma.net/peritoneal-mesothelioma/ Peritoneal Mesothelioma \| Mesothelioma.net]</ref> Approximately 25% of mesothelioma patients receive an initial misdiagnosis, often as pneumonia, COPD, or lung cancer, delaying definitive treatment and reducing survival options.<ref name="dandelldiagnosis">[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Information \| Danziger & De Llano]</ref><ref name="ncimeso" /> Histological cell type—epithelioid (70-80%), sarcomatoid (10-15%), or biphasic (10-15%)—substantially affects prognosis and symptom severity, with sarcomatoid variants presenting earlier with more aggressive pain and constitutional symptoms.<ref name="mlcdiseases">[https://www.mesotheliomalawyercenter.org/asbestos/diseases/ Asbestos-Related Diseases \| Mesothelioma Lawyer Center]</ref><ref name="ncimeso" /> Emerging biomarker advances in 2024-2026, including circulating microRNA panels, volatile organic compound breath analysis, and chromosomal rearrangement liquid biopsy, may enable earlier detection in high-risk asbestos-exposed populations.<ref name="mesoattsymptoms">[https://mesotheliomaattorney.com/mesothelioma/symptoms/ Mesothelioma Symptoms \| Mesothelioma Attorney]</ref><ref name="pmcbiomarkers">[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504120/ Chen Z, Gaudino G, Pass HI, et al. Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. ''Transl Lung Cancer Res.'' 2017;6(3):259-269.]</ref> Early recognition of symptoms and immediate medical consultation are critical for treatment eligibility and preserving legal claims.

	== Key Facts ==		== Key Facts ==
Line 197:		Line 197:
	* Benign ascites from other causes		* Benign ascites from other causes

	The insidious abdominal presentation differs markedly from respiratory symptoms of pleural mesothelioma, causing diagnostic delays when clinicians fail to connect abdominal symptoms to asbestos exposure history.		The insidious abdominal presentation differs markedly from respiratory symptoms of pleural mesothelioma, causing diagnostic delays when clinicians fail to connect abdominal symptoms to [[Asbestos Exposure\|asbestos exposure]] history.

	== What Are Pericardial and Testicular Mesothelioma Symptoms? ==		== What Are Pericardial and Testicular Mesothelioma Symptoms? ==
Line 316:		Line 316:
	* '''Performance Status:''' ECOG 0-1 (fully functional to slight activity limitation)		* '''Performance Status:''' ECOG 0-1 (fully functional to slight activity limitation)
	* '''Prognosis:''' Best outcomes; 5-year survival approximately 24% with treatment<ref name="seermeso" />		* '''Prognosis:''' Best outcomes; 5-year survival approximately 24% with treatment<ref name="seermeso" />
	* '''Treatment Options:''' Maximum surgical and chemotherapy eligibility; candidates for [[Mesothelioma Treatment Centers\|extrapleural pneumonectomy (EPP)]] or [[Pleural Mesothelioma\|pleurectomy/decortication (P/D)]]		* '''[[Treatment Options]]:''' Maximum surgical and chemotherapy eligibility; candidates for [[Mesothelioma Treatment Centers\|extrapleural pneumonectomy (EPP)]] or [[Pleural Mesothelioma\|pleurectomy/decortication (P/D)]]

	=== Stage II: Local Extension into Diaphragm or Lung ===		=== Stage II: Local Extension into Diaphragm or Lung ===
Line 429:		Line 429:
	** Pleurectomy/decortication (P/D) — lung-sparing surgery option lost in Stage IV disease		** Pleurectomy/decortication (P/D) — lung-sparing surgery option lost in Stage IV disease
	** Multimodal therapy (surgery + chemotherapy + radiation) — increasingly limited at Stage III-IV		** Multimodal therapy (surgery + chemotherapy + radiation) — increasingly limited at Stage III-IV
	** Clinical trials requiring good performance status		** [[Clinical Trials\|Clinical trials]] requiring good performance status

	* '''Survival Differential:''' Localized disease (Stage I) has 24% 5-year survival vs. 7% for metastatic disease—a difference of more than 17 percentage points driven substantially by stage at diagnosis.		* '''Survival Differential:''' Localized disease (Stage I) has 24% 5-year survival vs. 7% for metastatic disease—a difference of more than 17 percentage points driven substantially by stage at diagnosis.

MesotheliomaSupport: Internal linking: added 4 wiki links

2026-02-20T20:53:37Z

Internal linking: added 4 wiki links

← Older revision		Revision as of 20:53, 20 February 2026
Line 42:		Line 42:
	== Executive Summary ==		== Executive Summary ==

	Mesothelioma symptoms are notoriously nonspecific and frequently misdiagnosed, contributing to a diagnostic delay averaging 9 months from initial symptom onset.<ref name="ncimeso">[https://www.cancer.gov/types/mesothelioma Malignant Mesothelioma Treatment (PDQ) – Health Professional Version, National Cancer Institute]</ref> Pleural mesothelioma accounts for approximately 81% of cases and typically presents with progressive dyspnea (59%), chest pain (53%), and pleural effusion (86%).<ref name="dandellsymptoms">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-symptoms-guide/ Mesothelioma Symptoms Guide \| Danziger & De Llano]</ref><ref name="pmcsymptoms">[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090860/ Garcia-Prieto CA, et al. Clinical characteristics and outcomes in malignant pleural mesothelioma: a single-center experience. ''Cancers.'' 2024;16(9):1712.]</ref> Peritoneal mesothelioma affects 15-20% of patients with abdominal pain (69%) and ascites (77%) as predominant features, while pericardial and testicular variants represent fewer than 2% of cases each and are frequently diagnosed posthumously.<ref name="mesonetperitoneal">[https://mesothelioma.net/peritoneal-mesothelioma/ Peritoneal Mesothelioma \| Mesothelioma.net]</ref> Approximately 25% of mesothelioma patients receive an initial misdiagnosis, often as pneumonia, COPD, or lung cancer, delaying definitive treatment and reducing survival options.<ref name="dandelldiagnosis">[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Information \| Danziger & De Llano]</ref><ref name="ncimeso" /> Histological cell type—epithelioid (70-80%), sarcomatoid (10-15%), or biphasic (10-15%)—substantially affects prognosis and symptom severity, with sarcomatoid variants presenting earlier with more aggressive pain and constitutional symptoms.<ref name="mlcdiseases">[https://www.mesotheliomalawyercenter.org/asbestos/diseases/ Asbestos-Related Diseases \| Mesothelioma Lawyer Center]</ref><ref name="ncimeso" /> Emerging biomarker advances in 2024-2026, including circulating microRNA panels, volatile organic compound breath analysis, and chromosomal rearrangement liquid biopsy, may enable earlier detection in high-risk asbestos-exposed populations.<ref name="mesoattsymptoms">[https://mesotheliomaattorney.com/mesothelioma/symptoms/ Mesothelioma Symptoms \| Mesothelioma Attorney]</ref><ref name="pmcbiomarkers">[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504120/ Chen Z, Gaudino G, Pass HI, et al. Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. ''Transl Lung Cancer Res.'' 2017;6(3):259-269.]</ref> Early recognition of symptoms and immediate medical consultation are critical for treatment eligibility and preserving legal claims.		[[Mesothelioma]] symptoms are notoriously nonspecific and frequently misdiagnosed, contributing to a diagnostic delay averaging 9 months from initial symptom onset.<ref name="ncimeso">[https://www.cancer.gov/types/mesothelioma Malignant Mesothelioma Treatment (PDQ) – Health Professional Version, National Cancer Institute]</ref> Pleural mesothelioma accounts for approximately 81% of cases and typically presents with progressive dyspnea (59%), chest pain (53%), and pleural effusion (86%).<ref name="dandellsymptoms">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-symptoms-guide/ Mesothelioma Symptoms Guide \| Danziger & De Llano]</ref><ref name="pmcsymptoms">[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090860/ Garcia-Prieto CA, et al. Clinical characteristics and outcomes in malignant pleural mesothelioma: a single-center experience. ''Cancers.'' 2024;16(9):1712.]</ref> Peritoneal mesothelioma affects 15-20% of patients with abdominal pain (69%) and ascites (77%) as predominant features, while pericardial and testicular variants represent fewer than 2% of cases each and are frequently diagnosed posthumously.<ref name="mesonetperitoneal">[https://mesothelioma.net/peritoneal-mesothelioma/ Peritoneal Mesothelioma \| Mesothelioma.net]</ref> Approximately 25% of mesothelioma patients receive an initial misdiagnosis, often as pneumonia, COPD, or lung cancer, delaying definitive treatment and reducing survival options.<ref name="dandelldiagnosis">[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Information \| Danziger & De Llano]</ref><ref name="ncimeso" /> Histological cell type—epithelioid (70-80%), sarcomatoid (10-15%), or biphasic (10-15%)—substantially affects prognosis and symptom severity, with sarcomatoid variants presenting earlier with more aggressive pain and constitutional symptoms.<ref name="mlcdiseases">[https://www.mesotheliomalawyercenter.org/asbestos/diseases/ Asbestos-Related Diseases \| Mesothelioma Lawyer Center]</ref><ref name="ncimeso" /> Emerging biomarker advances in 2024-2026, including circulating microRNA panels, volatile organic compound breath analysis, and chromosomal rearrangement liquid biopsy, may enable earlier detection in high-risk asbestos-exposed populations.<ref name="mesoattsymptoms">[https://mesotheliomaattorney.com/mesothelioma/symptoms/ Mesothelioma Symptoms \| Mesothelioma Attorney]</ref><ref name="pmcbiomarkers">[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504120/ Chen Z, Gaudino G, Pass HI, et al. Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. ''Transl Lung Cancer Res.'' 2017;6(3):259-269.]</ref> Early recognition of symptoms and immediate medical consultation are critical for treatment eligibility and preserving legal claims.

	== Key Facts ==		== Key Facts ==
Line 72:		Line 72:
	In localized disease, symptoms are often subtle and mimic benign respiratory conditions:		In localized disease, symptoms are often subtle and mimic benign respiratory conditions:

	* '''Dyspnea (Shortness of Breath) — 59%:''' Usually the first symptom, related to pleural effusion restricting lung expansion. Patients often attribute this to aging or occupational lung disease. Severity typically increases gradually over weeks to months. Progressive dyspnea in older patients with asbestos exposure history is frequently misattributed to COPD or heart disease.<ref name="mesonetpleural">[https://mesothelioma.net/pleural-mesothelioma/ Pleural Mesothelioma \| Mesothelioma.net]</ref><ref name="pmcsymptoms" />		* '''Dyspnea (Shortness of Breath) — 59%:''' Usually the first symptom, related to pleural effusion restricting lung expansion. Patients often attribute this to aging or occupational lung disease. Severity typically increases gradually over weeks to months. Progressive dyspnea in older patients with [[Asbestos Exposure\|asbestos exposure]] history is frequently misattributed to COPD or heart disease.<ref name="mesonetpleural">[https://mesothelioma.net/pleural-mesothelioma/ Pleural Mesothelioma \| Mesothelioma.net]</ref><ref name="pmcsymptoms" />

	* '''Chest Pain — 53%:''' Dull, persistent, or pleuritic (sharp with breathing). May be localized to the affected side or diffuse. Pain stems from pleural invasion and tumor growth along the chest wall. Early chest pain may be attributed to muscle strain or heart disease. Pain intensity correlates with degree of chest wall and diaphragmatic involvement.		* '''Chest Pain — 53%:''' Dull, persistent, or pleuritic (sharp with breathing). May be localized to the affected side or diffuse. Pain stems from pleural invasion and tumor growth along the chest wall. Early chest pain may be attributed to muscle strain or heart disease. Pain intensity correlates with degree of chest wall and diaphragmatic involvement.
Line 273:		Line 273:
	{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "Patients are frequently told they have COPD, pneumonia, or heart disease for months or even years before the correct mesothelioma diagnosis is made. By that time, the cancer has advanced significantly, and treatment options have been lost. That diagnostic delay is a critical legal and medical issue."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "Patients are frequently told they have COPD, pneumonia, or heart disease for months or even years before the correct mesothelioma diagnosis is made. By that time, the cancer has advanced significantly, and [[Treatment Options\|treatment options]] have been lost. That diagnostic delay is a critical legal and medical issue."
	\|-		\|-
	\| style="padding:5px 25px 20px; text-align:right;" \| '''— Rod De Llano,''' Founding Partner, Danziger & De Llano		\| style="padding:5px 25px 20px; text-align:right;" \| '''— Rod De Llano,''' Founding Partner, Danziger & De Llano
Line 377:		Line 377:
	=== Quality of Life Assessment ===		=== Quality of Life Assessment ===

	Two validated instruments are used in mesothelioma clinical trials:		Two validated instruments are used in mesothelioma [[Clinical Trials\|clinical trials]]:

	* '''LCSS-Meso''' (Lung Cancer Symptom Scale for Mesothelioma)—mesothelioma-specific quality of life instrument		* '''LCSS-Meso''' (Lung Cancer Symptom Scale for Mesothelioma)—mesothelioma-specific quality of life instrument

MesotheliomaSupport: Internal linking: added 4 wiki links

2026-02-20T20:47:09Z

Internal linking: added 4 wiki links

MesotheliomaSupport: Fix references section: replace explicit ref list with for proper footnote rendering

2026-02-07T00:02:06Z

Fix references section: replace explicit ref list with <references /> for proper footnote rendering

@@ Line 452: / Line 452: @@
 == References ==
-<references>
+<references />
 [[Category:Mesothelioma]]

MesotheliomaSupport: Fix broken SEER statfacts/meso.html 404→CDC mesothelioma incidence page

2026-02-06T22:53:22Z

Fix broken SEER statfacts/meso.html 404→CDC mesothelioma incidence page

← Older revision		Revision as of 22:53, 6 February 2026
Line 51:		Line 51:
	\|-		\|-
	\| style="padding:15px;" \|		\| style="padding:15px;" \|
	* '''Pleural Mesothelioma (81% of cases):''' Most common symptoms are dyspnea (59%), chest pain (53%), and cough (37%); pleural effusion present in 86% at diagnosis<ref name="pmcsymptoms" /><ref name="seermeso">[https://~~seer~~.~~cancer~~.gov/~~statfacts~~/~~html~~/~~meso~~.html ~~Cancer Stat Facts:~~ Mesothelioma, ~~National~~ Cancer ~~Institute Surveillance, Epidemiology~~, and ~~End Results Program~~]</ref>		* '''Pleural Mesothelioma (81% of cases):''' Most common symptoms are dyspnea (59%), chest pain (53%), and cough (37%); pleural effusion present in 86% at diagnosis<ref name="pmcsymptoms" /><ref name="seermeso">[https://www.cdc.gov/united-states-cancer-statistics/publications/mesothelioma.html Incidence of Malignant Mesothelioma, U.S. Cancer Statistics, Centers for Disease Control and Prevention]</ref>
	* '''Peritoneal Mesothelioma (15-20% of cases):''' Abdominal pain (69%), ascites/fluid accumulation (77%), asthenia/weakness (43%), weight loss (32%), and abdominal mass (30%)		* '''Peritoneal Mesothelioma (15-20% of cases):''' Abdominal pain (69%), ascites/fluid accumulation (77%), asthenia/weakness (43%), weight loss (32%), and abdominal mass (30%)
	* '''Pericardial Mesothelioma (<1-2% of cases):''' Fewer than 350 cases documented; presents with chest pain and cardiac symptoms; majority diagnosed posthumously; median survival 2-6 months		* '''Pericardial Mesothelioma (<1-2% of cases):''' Fewer than 350 cases documented; presents with chest pain and cardiac symptoms; majority diagnosed posthumously; median survival 2-6 months
Line 455:		Line 455:
	<ref name="pmcsymptoms">[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090860/ Garcia-Prieto CA, et al. Clinical characteristics and outcomes in malignant pleural mesothelioma: a single-center experience. ''Cancers.'' 2024;16(9):1712.]</ref>		<ref name="pmcsymptoms">[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090860/ Garcia-Prieto CA, et al. Clinical characteristics and outcomes in malignant pleural mesothelioma: a single-center experience. ''Cancers.'' 2024;16(9):1712.]</ref>
	<ref name="ncimeso">[https://www.cancer.gov/types/mesothelioma Malignant Mesothelioma Treatment (PDQ) – Health Professional Version, National Cancer Institute]</ref>		<ref name="ncimeso">[https://www.cancer.gov/types/mesothelioma Malignant Mesothelioma Treatment (PDQ) – Health Professional Version, National Cancer Institute]</ref>
	<ref name="seermeso">[https://~~seer~~.~~cancer~~.gov/~~statfacts~~/~~html~~/~~meso~~.html ~~Cancer Stat Facts:~~ Mesothelioma, ~~National~~ Cancer ~~Institute Surveillance, Epidemiology~~, and ~~End Results Program~~]</ref>		<ref name="seermeso">[https://www.cdc.gov/united-states-cancer-statistics/publications/mesothelioma.html Incidence of Malignant Mesothelioma, U.S. Cancer Statistics, Centers for Disease Control and Prevention]</ref>
	<ref name="pmcbiomarkers">[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504120/ Chen Z, Gaudino G, Pass HI, et al. Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. ''Transl Lung Cancer Res.'' 2017;6(3):259-269.]</ref>		<ref name="pmcbiomarkers">[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504120/ Chen Z, Gaudino G, Pass HI, et al. Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. ''Transl Lung Cancer Res.'' 2017;6(3):259-269.]</ref>
	<ref name="cdcasbestos">[https://www.cdc.gov/niosh/topics/asbestos/ Asbestos, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention]</ref>		<ref name="cdcasbestos">[https://www.cdc.gov/niosh/topics/asbestos/ Asbestos, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention]</ref>

MesotheliomaSupport: Comprehensive mesothelioma symptoms page: pleural, peritoneal, pericardial, testicular types; cell-type variations; biomarker advances 2024-2026; staging symptom progression; diagnostic delay analysis

2026-02-06T21:24:03Z

Comprehensive mesothelioma symptoms page: pleural, peritoneal, pericardial, testicular types; cell-type variations; biomarker advances 2024-2026; staging symptom progression; diagnostic delay analysis

Show changes

← Older revision		Revision as of 20:47, 20 February 2026
Line 9:		Line 9:
	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
	\|-		\|-
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Mesothelioma Symptoms		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| [[Mesothelioma]] Symptoms
	\|-		\|-
	\| style="padding:8px 12px; border-bottom:1px solid #dee2e6;" \| '''Most Common Type'''		\| style="padding:8px 12px; border-bottom:1px solid #dee2e6;" \| '''Most Common Type'''
Line 60:		Line 60:
	* '''Misdiagnosis Rate:''' Approximately 1 in 4 patients (25%) initially misdiagnosed as pneumonia, COPD, lung cancer, or heart disease		* '''Misdiagnosis Rate:''' Approximately 1 in 4 patients (25%) initially misdiagnosed as pneumonia, COPD, lung cancer, or heart disease
	* '''Symptom Progression:''' Early disease presents with subtle symptoms; advanced stage involves severe dyspnea, refractory pain, weight loss, and constitutional symptoms		* '''Symptom Progression:''' Early disease presents with subtle symptoms; advanced stage involves severe dyspnea, refractory pain, weight loss, and constitutional symptoms
	* '''Latency Period:''' 20-50+ years between asbestos exposure and symptom onset; median latency approximately 30-40 years<ref name="cdcasbestos">[https://www.cdc.gov/niosh/topics/asbestos/ Asbestos, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention]</ref>		* '''Latency Period:''' 20-50+ years between [[Asbestos Exposure\|asbestos exposure]] and symptom onset; median latency approximately 30-40 years<ref name="cdcasbestos">[https://www.cdc.gov/niosh/topics/asbestos/ Asbestos, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention]</ref>
	* '''Treatment Impact:''' Delayed diagnosis significantly reduces surgical options; localized disease (Stage I) has 24% 5-year survival vs. 7% for metastatic disease<ref name="seermeso" />		* '''Treatment Impact:''' Delayed diagnosis significantly reduces surgical options; localized disease (Stage I) has 24% 5-year survival vs. 7% for metastatic disease<ref name="seermeso" />
	\|}		\|}
Line 109:		Line 109:
	{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "The progression from nonspecific respiratory symptoms to advanced mesothelioma happens gradually over months to years. Many patients continue working and attributing symptoms to aging or occupational lung disease until breathing becomes severely compromised. By that point, treatment options have been significantly reduced."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "The progression from nonspecific respiratory symptoms to advanced mesothelioma happens gradually over months to years. Many patients continue working and attributing symptoms to aging or occupational lung disease until breathing becomes severely compromised. By that point, [[Treatment Options\|treatment options]] have been significantly reduced."
	\|-		\|-
	\| style="padding:5px 25px 20px; text-align:right;" \| '''— Paul Danziger,''' Founding Partner, Danziger & De Llano		\| style="padding:5px 25px 20px; text-align:right;" \| '''— Paul Danziger,''' Founding Partner, Danziger & De Llano
Line 292:		Line 292:
	'''Circulating microRNA Panels:''' A 2025 study published in ''Lung Cancer'' evaluated plasma microRNA ratios (miR-24-3p, miR-146a-5p, miR-191-5p, miR-200a-3p, miR-222-3p, miR-223-3p, miR-1260a) in 32 asbestos-exposed individuals and 56 pleural mesothelioma patients. The microRNA signatures robustly differentiated mesothelioma from asbestos exposure with high accuracy and enabled prognostic stratification into high- and low-risk groups—a significant advance for non-invasive biomarker monitoring. These microRNA patterns may enable screening of high-risk asbestos-exposed workers.		'''Circulating microRNA Panels:''' A 2025 study published in ''Lung Cancer'' evaluated plasma microRNA ratios (miR-24-3p, miR-146a-5p, miR-191-5p, miR-200a-3p, miR-222-3p, miR-223-3p, miR-1260a) in 32 asbestos-exposed individuals and 56 pleural mesothelioma patients. The microRNA signatures robustly differentiated mesothelioma from asbestos exposure with high accuracy and enabled prognostic stratification into high- and low-risk groups—a significant advance for non-invasive biomarker monitoring. These microRNA patterns may enable screening of high-risk asbestos-exposed workers.

	'''Volatile Organic Compound (VOC) Breath Analysis:''' A 2025 meta-analysis of 8 clinical trials involving 859 subjects found that VOCs in exhaled breath achieved pooled sensitivity of 86%, specificity of 73%, and AUC of 0.88 for distinguishing mesothelioma from healthy controls. A separate proof-of-concept study demonstrated 89% accuracy in distinguishing stable from progressive disease during treatment follow-up. Electronic nose (eNose) technology shows particular promise as a non-invasive, repeatable monitoring tool that could be deployed in occupational health settings.		'''Volatile Organic Compound (VOC) Breath Analysis:''' A 2025 meta-analysis of 8 [[Clinical Trials\|clinical trials]] involving 859 subjects found that VOCs in exhaled breath achieved pooled sensitivity of 86%, specificity of 73%, and AUC of 0.88 for distinguishing mesothelioma from healthy controls. A separate proof-of-concept study demonstrated 89% accuracy in distinguishing stable from progressive disease during treatment follow-up. Electronic nose (eNose) technology shows particular promise as a non-invasive, repeatable monitoring tool that could be deployed in occupational health settings.

	'''Chromosomal Rearrangement Liquid Biopsy (Mayo Clinic 2024):''' A Mayo Clinic proof-of-concept study developed novel strategy targeting chromosomal rearrangements (rather than point mutations) using whole-genome sequencing to detect mesothelioma circulating tumor DNA in blood. This represents significant methodological advance, as mesothelioma has low single-point mutation burden that limits traditional liquid biopsy approaches. This technology may enable blood-based detection in asbestos-exposed populations.		'''Chromosomal Rearrangement Liquid Biopsy (Mayo Clinic 2024):''' A Mayo Clinic proof-of-concept study developed novel strategy targeting chromosomal rearrangements (rather than point mutations) using whole-genome sequencing to detect mesothelioma circulating tumor DNA in blood. This represents significant methodological advance, as mesothelioma has low single-point mutation burden that limits traditional liquid biopsy approaches. This technology may enable blood-based detection in asbestos-exposed populations.